Filing Flows › Anika Therapeutics (ANIK) › Guidance & outlook
Anika Therapeutics (ANIK) guidance and outlook
Anika Therapeutics (ANIK) raised its guidance on Nov 6, 2026: Revenue +6% to +10% for FY2026; EBITDA margin 15%–17% for FY2026; Revenue +5% for FY2027. Anika Therapeutics' 10-Q filed Nov 6, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +6% to +10% | raised |
| Revenue | FY2026 | +5% to +9% | raised |
| EBITDA margin | FY2026 | 15%–17% | raised |
| Revenue | FY2027 | +5% | reaffirmed |
| Revenue | FY2027 | +5% to +15% | new |
From the earnings release filed Nov 6, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- As we look forward to the future, our business is positioned to capture value within our target markets of OA pain management and regenerative solutions.
- We believe our future success will be driven by our:
- Chemistry, Manufacturing and Controls, or CMC, activities required for approval of HA as a drug also remain a key milestone in the regulatory pathway and are expected to be a primary focus as we advance toward filing.
- We are targeting to make the NDA submission by December 31, 2027.
- We continue to believe strongly in Hyalofast’s potential in the U.S. market, and we will continue discussions with the FDA regarding the evidence that may be required to support future approval.
- Our effective tax rate for the three-month and nine-month periods ended September 30, 2026, was primarily driven by the full valuation on our deferred tax assets in the United States and our projected taxable income resulting in current tax expense in 2026.
- We expect that our requirements for cash to fund these uses will increase as our operations expand.
- We continue to generate cash from operating activities and believe that our operating cash flows, cash currently on our balance sheet and availability under our credit facility will be sufficient to allow us to continue to invest in our existing business, to manage our capital structure on a short and long-term basis, and to meet our anticipated operating cash needs.
Anika Therapeutics' latest quarter
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Anika Therapeutics raise or lower its guidance?
Anika Therapeutics (ANIK) raised its guidance on Nov 6, 2026: Revenue +6% to +10% for FY2026; EBITDA margin 15%–17% for FY2026; Revenue +5% for FY2027.
What does Anika Therapeutics expect?
As we look forward to the future, our business is positioned to capture value within our target markets of OA pain management and regenerative solutions. We believe our future success will be driven by our: Chemistry, Manufacturing and Controls, or CMC, activities required for approval of HA as a drug also remain a key milestone in the regulatory pathway and are expected to be a primary focus as we advance toward filing.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.